Ascentage Pharma Group International (HKSE:06855) Long-Term Capital Lease Obligation : HK$22 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Long-Term Capital Lease Obligation?

Ascentage Pharma Group International's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$22 Mil.

Ascentage Pharma Group International's quarterly Long-Term Capital Lease Obligation declined from Dec. 2023 (HK$14 Mil) to Jun. 2024 (HK$12 Mil) but then increased from Jun. 2024 (HK$12 Mil) to Dec. 2024 (HK$22 Mil).

Ascentage Pharma Group International's annual Long-Term Capital Lease Obligation increased from Dec. 2022 (HK$10 Mil) to Dec. 2023 (HK$14 Mil) and increased from Dec. 2023 (HK$14 Mil) to Dec. 2024 (HK$22 Mil).

Ascentage Pharma Group International Long-Term Capital Lease Obligation Historical Data

The historical data trend for Ascentage Pharma Group International's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Long-Term Capital Lease Obligation Chart

Ascentage Pharma Group International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

7.21

10.10

10.21

14.14

22.20

Ascentage Pharma Group International Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial											10.21	12.99	14.14	12.29	22.20

Ascentage Pharma Group International (HKSE:06855) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Ascentage Pharma Group International Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

AAPG:USA 36X:Germany

Address

68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website

https://www.ascentagepharma.com

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Takeda Pharmaceuticals International Ag	2101 Beneficial owner
Takeda Pharmaceuticals Company Limited	2201 Interest of corporation controlled by you
Gao Sharon Xia
Zhai Yifan
Yang Dajun
Wang Shaomeng
Li Ju-yun
Healthquest Pharma Limited
Guo Edward Ming
Ascentage Limited
South Dakota Trust Company Llc	2301 Trustee
Tian Yuan	2201 Interest of corporation controlled by you
Zhao Li	2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you

Ascentage Pharma Group International Headlines

No Headlines